Celldex/$CLDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Ticker
$CLDX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
186
ISIN
US15117B2025
Website
Celldex Metrics
BasicAdvanced
$1.5B
-
-$2.70
1.14
-
Price and volume
Market cap
$1.5B
Beta
1.14
52-week high
$46.86
52-week low
$14.40
Average daily volume
1.2M
Financial strength
Current ratio
21.668
Quick ratio
21.062
Long term debt to equity
0.274
Total debt to equity
0.488
Profitability
EBITDA (TTM)
-213.94
Gross margin (TTM)
-2,340.84%
Net profit margin (TTM)
-2,366.07%
Operating margin (TTM)
-2,873.52%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-16.88%
Return on equity (TTM)
-23.20%
Valuation
Price to revenue (TTM)
198.846
Price to book
2.14
Price to tangible book (TTM)
2.28
Price to free cash flow (TTM)
-8.671
Free cash flow yield (TTM)
-11.53%
Free cash flow per share (TTM)
-261.57%
Growth
Revenue change (TTM)
24.49%
Earnings per share change (TTM)
-4.32%
3-year revenue growth (CAGR)
22.22%
10-year revenue growth (CAGR)
7.53%
3-year earnings per share growth (CAGR)
16.09%
10-year earnings per share growth (CAGR)
-18.02%
What the Analysts think about Celldex
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Bulls say / Bears say
Celldex's lead candidate, barzolvolimab, demonstrated promising results in Phase 2 trials for chronic spontaneous urticaria, achieving significant decreases in disease activity, which supports its progression to Phase 3 studies. (reuters.com)
The company maintains a strong financial position with $725.3 million in cash and securities as of December 31, 2024, providing a cash runway through 2027, enabling sustained investment in its pipeline. (finviz.com)
Analysts have set an average 12-month price target of $60.00 for Celldex, indicating a potential upside from its current trading price. (nasdaq.com)
Celldex reported a net loss of $53.8 million for Q1 2025, with an adjusted loss per share of $0.81, missing analyst expectations and reflecting increased R&D expenses. (reuters.com)
Goldman Sachs initiated coverage with a 'Neutral' rating and a $45.00 price target, suggesting limited near-term upside potential. (nasdaq.com)
Competitor data indicates that briquilimab achieved an 83% complete response rate in treating chronic inducible urticaria, posing a competitive threat to Celldex's barzolvolimab, which had a 95% response rate but with noted side effects. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Celldex Financial Performance
Revenues and expenses
Celldex Earnings Performance
Company profitability
Celldex News
AllArticlesVideos
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
GlobeNewsWire·4 weeks ago
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
GlobeNewsWire·4 weeks ago
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celldex stock?
Celldex (CLDX) has a market cap of $1.5B as of July 11, 2025.
What is the P/E ratio for Celldex stock?
The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of July 11, 2025.
Does Celldex stock pay dividends?
No, Celldex (CLDX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Celldex dividend payment date?
Celldex (CLDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Celldex?
Celldex (CLDX) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.